^
Association details:
| Biomarker: | ZNF207 underexpression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug Class: | PD1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
System analysis based on the cancer–immunity cycle identifies ZNF207 as a novel immunotherapy target for hepatocellular carcinoma
Excerpt:
...patients in the ZNF207 low expression group exhibited a better response to PD1 monoclonal antibody treatment than the CTLA-4 monoclonal antibody...Receiver operating characteristic curve (ROC) analyses of the GSE78220 cohorts (PD1-treated cohort) revealed ZNF207 as a predictive biomarker for the efficacy of anti-PD1 therapy...
DOI:
http://dx.doi.org/10.1136/jitc-2021-004414
